Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$59.65T
24h Vol:
$11.26B
Dominance:
MSFT:5.18%
Stocklytics Platform
BETA
Instrument logo  BDX

Becton Dickinson and Co

BDX
60 / 100
S&P500
$235.31arrow_drop_down-0.10%-$0.24

Performance History

Stocklytics logo
Key Stats
Open$239.23
Prev. Close$239.14
EPS4.35
Dividend$3.68
Next Earnings DateJun 28, 2024
Dividend Yield %1.57%
Market Cap$68.40B
PE Ratio54.43
LOWHIGH
Day Range235.06
239.38
52 Week Range228.61
287.32
Ratios
P/B Ratio2.76
Revenue$19.37B
Operating M. %10.69%
Earnings$1.53B
Earnings Growth %-14.00%
EBITDA Margin %25.36%
ROE %5.13%
EPS4.35

Score Breakdown

60vs 53. Market Avg.

All Score 60 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

BDXMARKET
Value3939
Quality4440
Ownership3819
Growth7346
Dividends2637
warning

Becton Dickinson and Co's Earnings growth forecast for the next quarter of 0.16% is modest compared to market average of 0.29%. This indicates BDX could have limited growth.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$782.12
24H (%)arrow_drop_up3.77%
24H ($)$28.44
MARKET CAP$743.14B
PRICE$489.53
24H (%)arrow_drop_down-0.82%
24H ($)-$4.07
MARKET CAP$452.77B
PRICE$162.12
24H (%)arrow_drop_up0.45%
24H ($)$0.73
MARKET CAP$390.50B
PRICE$126.96
24H (%)arrow_drop_down-0.14%
24H ($)-$0.19
MARKET CAP$321.54B

About Becton Dickinson and Co (BDX)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Thomas E. Polen Jr.
Headquarters
Franklin Lakes
Employees
77000
Exchange
NYSE
add Becton Dickinson and Co to watchlist

Keep an eye on Becton Dickinson and Co

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Becton Dickinson and Co's (BDX) price per share?

The current price per share for Becton Dickinson and Co (BDX) is $235.31. The stock has seen a price change of -$0.24 recently, indicating a -0.1% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Becton Dickinson and Co (BDX)?

For Becton Dickinson and Co (BDX), the 52-week high is $287.32, which is 22.1% from the current price. The 52-week low is $228.62, the current price is 2.93% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Becton Dickinson and Co (BDX) a growth stock?

Becton Dickinson and Co (BDX) has shown an average price growth of 0.43% over the past three years. It has received a score of 53 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Becton Dickinson and Co as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Becton Dickinson and Co (BDX) stock price performance year to date (YTD)?

As of the latest data, Becton Dickinson and Co (BDX) has a year-to-date price change of -4.13%. Over the past month, the stock has experienced a price change of 0.14%. Over the last three months, the change has been -0.94%. Over the past six months, the figure is -13.76%. Looking at a longer horizon, the five-year price change stands at -6.94%.

question_mark
Is Becton Dickinson and Co (BDX) a profitable company?

Becton Dickinson and Co (BDX) has a net income of $1.53B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 42.17% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 10.69% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $19.37B, with a revenue growth rate of 2.66%, providing insight into the company's sales performance and growth. The gross profit is $8.17B. Operating income is noted at $2.11B. Furthermore, the EBITDA is $4.67B.

question_mark
What is the market capitalization of Becton Dickinson and Co (BDX)?

Becton Dickinson and Co (BDX) has a market capitalization of $67.98B. The average daily trading volume is 1.3M, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.